Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling

PP Lakhlani, DM Lovinger and LE Limbird

Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.

The alpha 2A-adrenergic receptor (alpha 2AAR), via its interaction with the pertussis toxin-sensitive Gi/G(o) class of G proteins, modulates multiple effector systems, including inhibition of adenylyl cyclase and Ca2+ channels and activation of K+ channels. Mutation of a membrane- embedded aspartate residue, highly conserved among G protein-coupled receptors, in the alpha 2AAR to asparagine (D79N alpha 2AAR) results in selective uncoupling of the receptor to K+ currents but retention of inhibition of cAMP production and of voltage-sensitive Ca2+ currents when expressed in AtT20 anterior pituitary cells in culture. It is known that attenuation of cAMP synthesis alone cannot account for alpha 2AAR suppression of stimulus-secretion coupling; thus, the D79N alpha 2AAR provides a unique tool with which to assess the relative contribution of K+ current activation and Ca2+ current suppression in mediating the cellular responses of alpha 2AAR. The wild-type alpha 2AAR suppresses basal and secretagogue-evoked adrenocorticotropic hormone (ACTH) release in a manner indistinguishable from response to the endogenous somatostatin receptor. In contrast, the D79N alpha 2AAR does not attenuate basal ACTH release and is only partially effective in suppressing ACTH secretion evoked by the secretagogue isoproterenol. Regulation of ACTH release evoked by 8-bromo-cAMP, which bypasses receptor regulation of cAMP synthesis, suggests that attenuation of cAMP production, although not sufficient for inhibition of ACTH secretion, nevertheless participates in a functionally relevant manner. Taken together, the present findings indicate that alpha 2AAR-mediated suppression of neuropeptide secretion requires concomitant regulation of K+ and Ca2+ currents in parallel with attenuation of cAMP production.

Volume 50, Issue 1, pp. 96-103, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				P. Belujon, E. Bezard, A. Taupignon, B. Bioulac, and A. Benazzouz Noradrenergic Modulation of Subthalamic Nucleus Activity: Behavioral and Electrophysiological Evidence in Intact and 6-Hydroxydopamine-Lesioned Rats J. Neurosci., September 5, 2007; 27(36): 9595 - 9606. [Abstract] [Full Text] [PDF]

				P. J. Pauwels, I. Rauly, and T. Wurch Dissimilar Pharmacological Responses by a New Series of Imidazoline Derivatives at Precoupled and Ligand-Activated {alpha}2A-Adrenoceptor States: Evidence for Effector Pathway-Dependent Differential Antagonism J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1015 - 1023. [Abstract] [Full Text] [PDF]

				M. H. Wilson, H. A. Highfield, and L. E. Limbird The Role of a Conserved Inter-Transmembrane Domain Interface in Regulating {alpha}2a-Adrenergic Receptor Conformational Stability and Cell-Surface Turnover Mol. Pharmacol., April 1, 2001; 59(4): 929 - 938. [Abstract] [Full Text]

				J. E. Donello, E. U. Padillo, M. L. Webster, L. A. Wheeler, and D. W. Gil {alpha}2-Adrenoceptor Agonists Inhibit Vitreal Glutamate and Aspartate Accumulation and Preserve Retinal Function after Transient Ischemia J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 216 - 223. [Abstract] [Full Text]

				P. P. Lakhlani, L. B. MacMillan, T. Z. Guo, B. A. McCool, D. M. Lovinger, M. Maze, and L. E. Limbird Substitution of a mutant alpha 2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo PNAS, September 2, 1997; 94(18): 9950 - 9955. [Abstract] [Full Text] [PDF]